Navigation Links
Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
Date:12/8/2008

PRINCETON, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today results from a preclinical study for MDX-1401, a second-generation non-fucosylated version of MDX-060 that targets CD30, a marker for activated lymphocytes that is present on the malignant cells of Hodgkin's lymphoma (HL) as well as other CD30-expressing cancers. MDX-1401 demonstrated almost a doubling in potency and efficacy in cell lines when compared to MDX-060. The improved potency and efficacy of MDX-1401 in in vivo xenograft models indicates enhanced antibody-dependent cellular cytotoxicity (ADCC) activity, an important mechanism of action of therapeutic antibodies. In addition to anti-tumor activity, the preclinical data showed a statistically significant increase in median survival time for the MDX-1401 treatment group when compared to the MDX-060 treatment group.

The data were presented in a poster presentation entitled "Characterization of MDX-1401, a human anti-CD30 antibody with enhanced effector function, for therapy of malignant lymphoma" (abstract #1580) at the 50th Annual Meeting of the American Society of Hematology (ASH) being held December 6-9, 2008 in San Francisco, CA.

"We are excited with the growing body of scientific evidence that indicates enhanced ADCC and improved anti-tumor efficacy with the second generation anti-CD30 antibody, MDX-1401, as compared to MDX-060," said Geoffrey M. Nichol, MBChB, Senior Vice President of Product Development at Medarex. "The data we have seen to date continues to inform our development plans and underscores the importance of assessing MDX-1401 as a potentially more potent therapeutic for CD-30 expressing malignancies. We look forward to presenting results from the ongoing Phase 1 MDX-1401 study and the recently completed Phase 2 MDX-060 study in 2009."


'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
2. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
3. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
4. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
5. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
6. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
9. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
10. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
11. Medarex Announces Ipilimumab Program Continues to Move Forward
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 EHE International, the recognized ... nationwide physician network, today announced that David Abrams M.D ... named an EHE-certified preventive care center. Through David Abrams ... region now have greater access to EHE,s preventive care ... "EHE is proud to add Dr. Abrams M.D. to its ...
(Date:9/16/2014)... BOSTON , Sept. 16, 2014 QPID ... a move to new headquarters in Boston ... The new headquarters will be at 175 Franklin Street in ... operations and marketing teams. QPID Health,s new Southern ... Parkway in Carlsbad.  The expansion will help meet the demands ...
(Date:9/16/2014)... 2014  Decision Resources Group finds that the rheumatoid arthritis (RA) ... to over $18.2 billion in 2023 in the United ... , Italy , Spain ... Japan . TNF-alpha inhibitors will remain the leading drug class ... growth will be constrained and patient shares will decline due to ...
Breaking Medicine Technology:EHE International Certifies David Abrams M.D. as Its Newest Partner 2QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3
... myeloma is one,of the most common and devastating bone ... dramatically over the past decade. Recent,analyses suggest that this ... aggressive therapeutic interventions such as stem cell transplantation,according to ... the,official journal of the American Society of Hematology., ...
... 1 Regado Biosciences today announced,the enrollment ... open-label,randomized Phase IIa clinical study, named REVERSAL-PCI, ... enrolled at Black Hills Cardiology,in Rapid City, ... undergoing elective,Percutaneous Coronary Intervention (PCI) to assess ...
Cached Medicine Technology:Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 2Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 3Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 4Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System 2Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System 3
(Date:9/16/2014)... 2014 An experienced review website, ... and announced that Bluehost and HostGator.com are among ... want to purchase high quality web hosting (including ... visit their websites now. , BlueHost ( ... established itself as a reliable and long-standing force ...
(Date:9/16/2014)... Pulmonary Hypertension Association Travels to San Diego for ... Patients and Families to Help Fight Rare Lung Disease , ... pulmonary hypertension association that works to find ways to prevent ... lungs that affects the functioning of the heart and can ... only 2.8 years. , What:, PHA On The ...
(Date:9/16/2014)... (PRWEB) September 17, 2014 ... hosting suppliers from the USA and announces ... ) are the best Windows web hosting ... on offering worldwide clients high quality WordPress ... low rates. , HostMonster provides outstanding ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, 2014 ... human papillomavirus (HPV), which is linked to the risk of ... that testing urine for HPV has good accuracy when compared ... lead researcher Dr. Neha Pathak. She is a resident in ... of London, England. The test could be done at ...
(Date:9/16/2014)... Advanced Fertility Center of Texas’ Dr. ... as one of the Top Doctors of 2014. The ... metropolitan magazine serving the Houston area. They award esteemed ... their outstanding services. This accomplishment will be included in ... — a special publication listing all the winners of ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: BlueHost and HostGator.com Are Among the Best Hosting Suppliers in 2014 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 3Health News:Best Windows Web Hosting Suppliers Recommended By SEO Hosting Review Site Top10BestSEOHosting.com 2Health News:Urine Test for HPV Works Well, Analysis Finds 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2
... Modifying gene called Foxp3 may develop cells capable of ... -- New understanding about how to control autoimmune responses ... arthritis (RA), British researchers say. , RA -- a ... body,s immune system attacks itself. A molecule called Foxp3 ...
... financial, operational, and clinical visibility to ... ... Fla., Nov. 13 Sentry Data Systems,today announced HealthBIT, a ... and clinical,visibility to hospitals by qualifying, aggregating, and comparing their,data ...
... Found with Free, Online Resources -, White ... paying out-of-pocket to fill prescriptions, and with those ... "Safe,Strategies for Drug Savings" today on its site ... in the U.S., Canada, and other,countries as well, ...
... Access to the Power of the Xevo TQ System,s Quantitative ... ... MILFORD, Mass., Nov. 13 Focused on the,process of helping firms ... ) will showcase innovative,UltraPerformance LC(R) (UPLC) and mass spectrometry (MS) solutions ...
... suite enables payors to compete like ... evolving healthcare marketplace, BURLINGTON, Mass., Nov. 13 ... platform for healthcare payors,today announced that it will ... 2008 Gartner Healthcare Summit. The,conference will be held ...
... Patients with advanced non-small cell lung cancer whose ... rate of tumor shrinkage and a longer interval ... standard second-line erlotinib therapy, according to a study ... Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and ...
Cached Medicine News:Health News:New Therapy Could Transform Arthritis Treatment 2Health News:Sentry Data Systems Announces Healthcare Business Intelligence Technology Platform 2Health News:PharmacyChecker.com Publishes 'Safe Strategies for Drug Savings' to Help All Americans Get Affordable Medication 2Health News:Waters To Unveil Xevo TQ MS Applications for Improved Drug Discovery at AAPS 2008 2Health News:Waters To Unveil Xevo TQ MS Applications for Improved Drug Discovery at AAPS 2008 3Health News:HealthEdge(R) Presents Award-Winning HealthRules(R) Technology Platform at the 2008 Gartner Healthcare Summit 2
80 inch PVC tubing with connectors and 19 gauge straight, beveled cannula. Fits Bausch & Lomb Surgical cassettes. Allows the safe removal of silicone oil in 10 minutes or less. 3/Box...
... gauge, 25 mm cannula with 30 gauge, 4.76 ... mm flattened tip. Cannula is attached to a ... ID x 8 inch long), for use with ... other vitreo-retinal membranes using visco elastic materials. Flattened, ...
20 gauge x 25 mm cannula with 30 degree x 5 mm tip. 30 gauge cannula extends into hub 2 mm from end of hub. 10 per box....
Developed for oculoplastic procedures for corneal and scleral protection. Dimensions enable protector to rest on the sclera and not on the cornea. Easily removed with Bishop-Harmon Forceps. Individua...
Medicine Products: